

July 10, 2012

For Immediate Release

Bristol-Myers K.K.
Public Affairs/Policy
Phone: +81-3-6705-7787

Ono Pharmaceutical Co., Ltd.
Corporate Communications
Phone: +81-6-6263-5670

**Bristol-Myers K.K. Files for Regulatory Approval in Japan
for ORENCIA® Subcutaneous Injection
(abatacept [rDNA]), Rheumatoid Arthritis Agent**

Bristol-Myers K.K. (Head Office: Shinjuku-ku, Tokyo; President & CEO: Emmanuel Blin; “BMKK”) and Ono Pharmaceutical Co., Ltd. (Head Office: Osaka City; President and Representative Director: Gyo Sagara; “Ono”) announced that BMKK filed an application with the Ministry of Health, Labour and Welfare on July 4, 2012 to obtain an approval for “ORENCIA® Subcutaneous Injection (abatacept [rDNA], “abatacept”).

Collaboration between Bristol Myers Squibb (“BMS”) and Ono

On September 21, 2011, the two companies entered into a collaboration agreement for ORENCIA®. The companies will co-promote ORENCIA 250mg Intravenous Injection, which BMKK has been distributing since September 2010, and also this Subcutaneous Injection, if approved, for which the new application was filed.

About ORENCIA® in Japan

Rheumatoid arthritis is an autoimmune disease characterized by inflammation of the joints as a result of the over-expression of pro-inflammatory cytokines. ORENCIA is a biologic therapy that works by inhibiting the T cell activation and suppressing the production of pro-inflammatory cytokines, which leads to the amelioration of the inflammation in joints of patients. ORENCIA IV is available in more than 50 countries, and was launched in September 2010 in Japan where it is indicated for use of rheumatoid arthritis only for patients with an inadequate response to prior conventional therapy.

About Bristol Myers K.K.

Bristol Myers K.K. is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit <http://www.bms.co.jp/>.

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a R&D-oriented pharmaceutical company specialized in creating innovative medicines in specific areas and is headquartered in Osaka, Japan. For more information about Ono, visit the company's website at www.ono.co.jp.

ORENCIA is a registered trademark of Bristol-Myers Squibb.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that Orencia SC will receive regulatory approval in Japan or, if approved, that it will become a commercially successful formulation. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2011, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Bristol-Myers Squibb

Public Affairs/Policy, +81-3-6705-7787

Hisashi Takanashi, hisashi.takanashi@bms.com

Ono Pharmaceutical Co., Ltd.

Corporate Communications, +81-6-6263-5670

Yukio Tani, y.tani@ono.co.jp